BiotechTube

ACT-541468 25 mg + ACT-541468 25 mg (or 10 mg depending on interim results)

Phase 1Completed
0 watching 0 views this week💤 Quiet
28
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hepatic Impairment

Conditions

Hepatic Impairment

Trial Timeline

Feb 26, 2018 → Feb 27, 2020

NCT ID
NCT03713242

About ACT-541468 25 mg + ACT-541468 25 mg (or 10 mg depending on interim results)

ACT-541468 25 mg + ACT-541468 25 mg (or 10 mg depending on interim results) is a phase 1 stage product being developed by Idorsia for Hepatic Impairment. The current trial status is completed. This product is registered under clinical trial identifier NCT03713242. Target conditions include Hepatic Impairment.

Hype Score Breakdown

Clinical
10
Activity
5
Company
5
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03713242Phase 1Completed

Competing Products

20 competing products in Hepatic Impairment

See all competitors
ProductCompanyStageHype Score
ITF2357BiotrialPhase 1
25
GB1211 + PlaceboComac MedicalPhase 1/2
33
OlomorasibEli LillyPhase 1
33
SimufilamCassava SciencesPhase 1
25
cisplatin + gemcitabine hydrochlorideEli LillyPhase 3
77
exatecan mesylateDaiichi SankyoPhase 2
52
DS-3201bDaiichi SankyoPhase 1
33
QuizartinibDaiichi SankyoPhase 1
33
QuizartinibDaiichi SankyoPhase 1
33
PexidartinibDaiichi SankyoPhase 1
33
Tivantinib + Tivantinib + Tivantinib + TivantinibDaiichi SankyoPhase 1
33
BocidelparAstellas PharmaPhase 1
33
fezolinetantAstellas PharmaPhase 1
33
enzalutamideAstellas PharmaPhase 1
33
ASP015KAstellas PharmaPhase 1
33
ASP2215Astellas PharmaPhase 1
33
BPN14770ShionogiPhase 1
33
S-217622ShionogiPhase 1
33
LemborexantEisaiPhase 1
33
LenvatinibEisaiPhase 1
33

Other Products from Idorsia

Daridorexant + PlaceboApproved
80
Daridorexant 50 mg + PlaceboApproved
80
Aprocitentan 12.5 mg + Aprocitentan 25 mg + PlaceboPhase 3
72
LucerastatPhase 3
72
Clazosentan + PlaceboPhase 3
72